异动解读｜Argenx SE盘前上涨3.85%，肌炎三期数据催化延续叠加机构上调目标价

行情直击08-26

8月26日，Argenx SE盘前上涨3.85%，报1058.75美元/股，成交额25.34万美元。消息面上，公司核心药物Vyvgart Hytrulo治疗自身免疫性肌炎的三期ALKIVIA试验此前达到主要终点，治疗组在第52周总改善评分较安慰剂高出15.4分，且为全球首个在免疫介导性坏死性肌病领域取得统计学显著改善的三期试验。

多家机构对此给出积极评价，Wedbush将目标价上调至1150美元，RBC、Morgan Stanley及Oppenheimer均认为该数据降低了Vyvgart约15至20亿美元肌炎市场机会的不确定性。公司此前二季度营收15.42亿美元超预期7%，EPS 7.32美元超预期17%，基本面持续强劲。此次盘前上涨或为前一交易日回调后的修复性反弹。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1182552700?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-26 18:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182552700","market":"hk","top_or_hot":-1,"title":"异动解读｜Argenx SE盘前上涨3.85%，肌炎三期数据催化延续叠加机构上调目标价","media":"行情直击","content":"<p><p>8月26日，Argenx SE盘前上涨3.85%，报1058.75美元/股，成交额25.34万美元。消息面上，公司核心药物Vyvgart Hytrulo治疗自身免疫性肌炎的三期ALKIVIA试验此前达到主要终点，治疗组在第52周总改善评分较安慰剂高出15.4分，且为全球首个在免疫介导性坏死性肌病领域取得统计学显著改善的三期试验。</p><p>多家机构对此给出积极评价，Wedbush将目标价上调至1150美元，RBC、Morgan Stanley及Oppenheimer均认为该数据降低了Vyvgart约15至20亿美元肌炎市场机会的不确定性。公司此前二季度营收15.42亿美元超预期7%，EPS 7.32美元超预期17%，基本面持续强劲。此次盘前上涨或为前一交易日回调后的修复性反弹。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜Argenx SE盘前上涨3.85%，肌炎三期数据催化延续叠加机构上调目标价</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜Argenx SE盘前上涨3.85%，肌炎三期数据催化延续叠加机构上调目标价\n</h2>\n\n<h4 class=\"meta\">\n\n2026-08-26 18:41 北京时间&nbsp;&nbsp;&nbsp;<strong>行情直击</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月26日，Argenx SE盘前上涨3.85%，报1058.75美元/股，成交额25.34万美元。消息面上，公司核心药物Vyvgart Hytrulo治疗自身免疫性肌炎的三期ALKIVIA试验此前达到主要终点，治疗组在第52周总改善评分较安慰剂高出15.4分，且为全球首个在免疫介导性坏死性肌病领域取得统计学显著改善的三期试验。多家机构对此给出积极评价，Wedbush将目标价上调至1150美元，...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARGX","symbol_name":"Argenx SE","start_time":0,"source_url":"","article_id":"1182552700","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182552700","pubTimestamp":1787740883,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"8月26日，Argenx SE盘前上涨3.85%，报1058.75美元/股，成交额25.34万美元。多家机构对此给出积极评价，Wedbush将目标价上调至1150美元，RBC、Morgan Stanley及Oppenheimer均认为该数据降低了Vyvgart约15至20亿美元肌炎市场机会的不确定性。公司此前二季度营收15.42亿美元超预期7%，EPS 7.32美元超预期17%，基本面持续强劲。此次盘前上涨或为前一交易日回调后的修复性反弹。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"ARGX":"Argenx SE"},"translate_title":"Movement Interpretation | Argenx SE rose 3.85% before the market, and the catalytic continuation of myositis Phase III data superimposed institutions raised their target price","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARGX":1},"content_text":"8月26日，Argenx SE盘前上涨3.85%，报1058.75美元/股，成交额25.34万美元。消息面上，公司核心药物Vyvgart Hytrulo治疗自身免疫性肌炎的三期ALKIVIA试验此前达到主要终点，治疗组在第52周总改善评分较安慰剂高出15.4分，且为全球首个在免疫介导性坏死性肌病领域取得统计学显著改善的三期试验。多家机构对此给出积极评价，Wedbush将目标价上调至1150美元，RBC、Morgan Stanley及Oppenheimer均认为该数据降低了Vyvgart约15至20亿美元肌炎市场机会的不确定性。公司此前二季度营收15.42亿美元超预期7%，EPS 7.32美元超预期17%，基本面持续强劲。此次盘前上涨或为前一交易日回调后的修复性反弹。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182552700","isCrawlerRequest":true}